Treats metastatic non-small cell lung cancer (NSCLC). ANDA 208913, held by Actavis Labs Fl Inc. Gefitinib.
As of Nov 16, 2026, ANDA 208913 (Gefitinib), held by Actavis Labs Fl Inc, was first approved by FDA on Apr 26, 2023, with 0 approved supplements and 0 published complete response letters.
Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 26, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Gefitinib250MG · tablet;oral | Gefitinib | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters